CMS Molecular Diagnostics Program expanded Medicare coverage for Personalis' ultrasensitive NeXT Personal® test to include immunotherapy monitoring for late-stage solid tumor patients on May 12, 2026.
Key takeaways
CMS expanded Medicare coverage for NeXT Personal® test on May 12, 2026.
Coverage now includes immunotherapy monitoring for late-stage solid tumors.
Applies to ultrasensitive molecular diagnostics program.
Enhances reimbursement access for oncology patient monitoring.